Y-mAbs Therapeutics (YMAB) News Today → Do This Before July 30 2024 To Claim Trump’s Gift (From Wealthpin Pro) (Ad) Free YMAB Stock Alerts $12.10 +0.09 (+0.75%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 1 at 8:56 AM | insidertrades.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CFO Sells $378,647.97 in StockJune 1 at 8:15 AM | globenewswire.comY-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual MeetingJune 1 at 8:05 AM | globenewswire.comY-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingMay 31 at 10:33 PM | marketbeat.comBo Kruse Sells 31,371 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) StockY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) CFO Bo Kruse sold 31,371 shares of the business's stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $12.07, for a total transaction of $378,647.97. Following the completion of the transaction, the chief financial officer now owns 210,877 shares in the company, valued at $2,545,285.39. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.May 31 at 8:30 AM | americanbankingnews.comY-mAbs Therapeutics (NASDAQ:YMAB) Sees Unusually-High Trading VolumeMay 30 at 3:02 AM | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Rating of "Hold" from BrokeragesMay 30 at 1:53 AM | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Consensus Rating of "Hold" by AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Hold" by the six brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation and four have issued a buy recommenMay 30 at 1:49 AM | americanbankingnews.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest UpdateMay 29 at 1:55 PM | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Sees Large Volume IncreaseY-mAbs Therapeutics (NASDAQ:YMAB) Sees Unusually-High Trading VolumeMay 25, 2024 | americanbankingnews.comThomas Gad Sells 7,351 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) StockMay 25, 2024 | americanbankingnews.comThomas Gad Sells 25,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) StockMay 24, 2024 | insidertrades.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Insider Sells $95,563.00 in StockMay 21, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Trading 3% Higher Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 3%May 15, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7.5%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 7.5% HigherMay 13, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Price Target Raised to $22.00HC Wainwright upped their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Monday.May 10, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 6.8%Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 6.8%May 9, 2024 | finance.yahoo.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Q1 2024 Earnings Call TranscriptMay 9, 2024 | seekingalpha.comY-mAbs: There's A Ceiling Here SomewhereMay 9, 2024 | finance.yahoo.comY-mAbs Therapeutics Inc (YMAB) Q1 2024 Earnings Call Transcript Highlights: Navigating ...May 9, 2024 | finance.yahoo.comQ1 2024 Y-mAbs Therapeutics Inc Earnings CallMay 8, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $17.21May 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Y-Mabs Therapeutics Amid Strong Danyelza Sales and Promising SADA Radiotherapy PlatformMay 7, 2024 | investorplace.comYMAB Stock Earnings: Y-mAbs Therapeutics Misses EPS, Misses Revenue for Q1 2024May 7, 2024 | tmcnet.comY-mAbs Reports First Quarter 2024 Financial Results and Recent Corporate DevelopmentsMay 7, 2024 | finance.yahoo.comY-mAbs Therapeutics Reports Q1 2024 Results: Aligns with EPS Projections, Misses Revenue EstimatesMay 7, 2024 | marketbeat.com43,700 Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Bought by Sapient Capital LLCSapient Capital LLC purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund purchased 43,700 shares of the company's stock, valued at approximately $298,000. Sapient CaApril 30, 2024 | marketbeat.comY-mAbs Therapeutics (YMAB) Set to Announce Quarterly Earnings on TuesdayY-mAbs Therapeutics (NASDAQ:YMAB) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=590317)April 26, 2024 | globenewswire.comY-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024April 25, 2024 | globenewswire.comY-mAbs to Present at 2024 ASCO Annual MeetingApril 23, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 7%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 7%April 18, 2024 | finance.yahoo.comY-mAbs Therapeutics (NASDAQ:YMAB) rises 9.6% this week, taking one-year gains to 161%April 11, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4%Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4%April 10, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Hold" by AnalystsY-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) has been given a consensus rating of "Hold" by the six ratings firms that are presently covering the company, MarketBeat Ratings reports. Two research analysts have rated the stock with a sell rating and four have assigned a buy rating toApril 9, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Down 3.3% Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.3%April 3, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 3.2%April 2, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $16.19April 1, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 5.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 5.9%April 1, 2024 | marketbeat.comDenali Advisors LLC Sells 69,500 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)Denali Advisors LLC lessened its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 80.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 16,400 shares of the company's stock afterMarch 26, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 3.9%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading 3.9% HigherMarch 19, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Up 4.3%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 4.3%March 15, 2024 | marketwatch.comY-mAbs Therapeutics Finance Chief Bo Kruse ResignsMarch 14, 2024 | finanznachrichten.deY-mAbs Therapeutics, Inc.: Y-mAbs Therapeutics Announces Resignation of Chief Financial OfficerMarch 14, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84Y-mAbs Therapeutics (NASDAQ:YMAB) Shares Gap Down to $15.84March 14, 2024 | markets.businessinsider.comY-mAbs Therapeutics CFO Bo Kruse To RetireMarch 14, 2024 | globenewswire.comY-mAbs Therapeutics Announces Resignation of Chief Financial OfficerMarch 13, 2024 | marketbeat.comGSA Capital Partners LLP Acquires 92,765 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)GSA Capital Partners LLP lifted its holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 208.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 137,299 shares of thMarch 11, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 8.3%Y-mAbs Therapeutics (NASDAQ:YMAB) Trading Down 8.3%March 11, 2024 | marketbeat.comY-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Holdings Raised by Trexquant Investment LPTrexquant Investment LP boosted its stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 417.5% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 76,585 shares of the company's stockMarch 6, 2024 | markets.businessinsider.comCracking The Code: Understanding Analyst Reviews For Y-mAbs TherapeuticsMarch 6, 2024 | marketbeat.comY-mAbs Therapeutics (NASDAQ:YMAB) Shares Up 8.2% Following Analyst UpgradeY-mAbs Therapeutics (NASDAQ:YMAB) Trading Up 8.2% After Analyst Upgrade Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address The #1 Crypto That You Don’t Own… Yet (Ad)There’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay attention to above all others: Venture capital firms. You want to follow venture capital money into cryptocurrencies before anyone gets word of what’s happening. Click here for all the details… YMAB Media Mentions By Week YMAB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. YMAB News Sentiment▼0.950.78▲Average Medical News Sentiment YMAB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. YMAB Articles This Week▼122▲YMAB Articles Average Week Get Y-mAbs Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for YMAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: HRTX News Today AMRN News Today AUPH News Today MRSN News Today GBIO News Today AMRX News Today AMPH News Today VERA News Today GERN News Today CPRX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:YMAB) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
